{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:30:12Z","timestamp":1789583412403,"version":"build-2803163510"},"reference-count":94,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Cardiol"],"abstract":"<jats:p>More than half of adults are overweight\/obese and one in 10 has chronic kidney disease (CKD). These patients are at high risk of cardiovascular morbidity and mortality. This review discusses the pathophysiology, epidemiology, therapeutic principles and challenges of obesity management in adults with non-dialysis-dependent CKD. Inflammation, metabolic dysfunction and neurohormonal changes are central processes in the development of obesity-associated kidney disease. Obesity with metabolic syndrome is a risk factor for de novo CKD, progression to end-stage kidney disease and cardiovascular death. Treatment options to address obesity and related sequelae include lifestyle interventions, such as dietary modification and exercise therapy, drug treatment, such as glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter inhibitors, and metabolic surgery, such as vertical sleeve gastrectomy, Roux-en-Y gastric bypass or gastric banding. Challenges of management include fragmented care, limited evidence and the obesogenic environment. Cardiologists and nephrologists should work collaboratively to proactively screen for and manage cardiorenal risk in obese adults with CKD to mitigate avoidable harm.<\/jats:p>","DOI":"10.15420\/ecr.2025.33","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T12:18:32Z","timestamp":1760703512000},"source":"Crossref","is-referenced-by-count":10,"title":["Obesity and Chronic Kidney Disease: The Dual Epidemic in Cardiovascular Health"],"prefix":"10.15420","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5249-5442","authenticated-orcid":false,"given":"Christopher Henry","family":"Grant","sequence":"first","affiliation":[{"name":"Division of Population Health and Genomics, School of Medicine, University of Dundee, Scotland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9100-1575","authenticated-orcid":false,"given":"Samira","family":"Bell","sequence":"additional","affiliation":[{"name":"Division of Population Health and Genomics, School of Medicine, University of Dundee, Scotland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"ref0","unstructured":"GBD 2021 Adult BMI Collaborators. Global, regional, and national prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet 2025;405:813\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(25)00355-1; PMID:\u00a040049186."},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Abdullah A, Peeters A, de Courten M, Stoelwinder J. The magnitude of association between overweight and obesity and the risk of diabetes: a meta-analysis of prospective cohort studies. Diabetes Res Clin Pract 2010;89:309\u201319. https:\/\/doi.org\/10.1016\/j.diabres.2010.04.012; PMID:\u00a020493574.","DOI":"10.1016\/j.diabres.2010.04.012"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Garrison RJ, Kannel WB, Stokes J, 3rd, Castelli WP. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 1987;16:235\u201351. https:\/\/doi.org\/10.1016\/0091-7435(87)90087-9; PMID:\u00a03588564.","DOI":"10.1016\/0091-7435(87)90087-9"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Kim MS, Kim WJ, Khera AV, et al. Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and Mendelian randomization studies. Eur Heart J 2021;42:3388\u2013403. https:\/\/doi.org\/10.1093\/eurheartj\/ehab454; PMID:\u00a034333589.","DOI":"10.1093\/eurheartj\/ehab454"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Mackenbach JD, Rutter H, Compernolle S, et al. Obesogenic environments: a systematic review of the association between the physical environment and adult weight status, the SPOTLIGHT project. BMC Public Health 2014;14:233. https:\/\/doi.org\/10.1186\/1471-2458-14-233; PMID:\u00a024602291.","DOI":"10.1186\/1471-2458-14-233"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011) 2022;12:7\u201311. https:\/\/doi.org\/10.1016\/j.kisu.2021.11.003; PMID:\u00a035529086.","DOI":"10.1016\/j.kisu.2021.11.003"},{"key":"ref6","unstructured":"Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016\u201340 for 195 countries and territories. Lancet 2018;392:2052\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(18)31694-5; PMID:\u00a030340847."},{"key":"ref7","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2024;105:S117\u2013314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018; PMID:\u00a038490803."},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Dalrymple LS, Katz R, Kestenbaum B, et al. Chronic kidney disease and the risk of end-stage renal disease versus death. J Gen Intern Med 2011;26:379\u201385. https:\/\/doi.org\/10.1007\/s11606-010-1511-x; PMID:\u00a020853156.","DOI":"10.1007\/s11606-010-1511-x"},{"key":"ref9","unstructured":"World Health Organization. Obesity. 2025. https:\/\/www.who.int\/health-topics\/obesity#tab=tab_1 (accessed 5 May 2025)."},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Bl\u00fcher M. Metabolically healthy obesity. Endocr Rev 2020;41:bnaa004. https:\/\/doi.org\/10.1210\/endrev\/bnaa004; PMID:\u00a032128581.","DOI":"10.1210\/endrev\/bnaa004"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Sweatt K, Garvey WT, Martins C. Strengths and limitations of BMI in the diagnosis of obesity: what is the path forward? Curr Obes Rep 2024;13:584\u201395. https:\/\/doi.org\/10.1007\/s13679-024-00580-1; PMID:\u00a038958869.","DOI":"10.1007\/s13679-024-00580-1"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Neeland IJ, Turer AT, Ayers CR, et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA 2012;308:1150\u20139. https:\/\/doi.org\/10.1001\/2012.jama.11132; PMID:\u00a022990274.","DOI":"10.1001\/2012.jama.11132"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Ndumele CE, Neeland IJ, Tuttle KR, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: A scientific statement from the American Heart Association. Circulation 2023;148:1636\u201364. https:\/\/doi.org\/10.1161\/CIR.0000000000001186; PMID:\u00a037807920.","DOI":"10.1161\/cir.0000000000001186"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Ellulu MS, Patimah I, Khaza\u2019ai H, et al. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci 2017;13:851\u201363. https:\/\/doi.org\/10.5114\/aoms.2016.58928; PMID:\u00a028721154.","DOI":"10.5114\/aoms.2016.58928"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836\u201343. https:\/\/doi.org\/10.1056\/NEJM200003233421202; PMID:\u00a010733371.","DOI":"10.1056\/nejm200003233421202"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Amdur RL, Feldman HI, Dominic EA, et al. Use of measures of inflammation and kidney function for prediction of atherosclerotic vascular disease events and death in patients with CKD: findings from the CRIC study. Am J Kidney Dis 2019;73:344\u201353. https:\/\/doi.org\/10.1053\/j.ajkd.2018.09.012; PMID:\u00a030545708.","DOI":"10.1053\/j.ajkd.2018.09.012"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Maric C, Hall JE. Obesity, metabolic syndrome and diabetic nephropathy. Contrib Nephrol 2011;170:28\u201335. https:\/\/doi.org\/10.1159\/000324941; PMID:\u00a021659755.","DOI":"10.1159\/000324941"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Griffin KA, Kramer H, Bidani AK. Adverse renal consequences of obesity. Am J Physiol Ren Physiol 2008;294:F685\u201396. https:\/\/doi.org\/10.1152\/ajprenal.00324.2007; PMID:\u00a018234955.","DOI":"10.1152\/ajprenal.00324.2007"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"King GL. The role of inflammatory cytokines in diabetes and its complications. J Periodontol 2008;79(8 Suppl):1527\u201334. https:\/\/doi.org\/10.1902\/jop.2008.080246; PMID:\u00a018673007.","DOI":"10.1902\/jop.2008.080246"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Clemente-Su\u00e1rez VJ, Redondo-Fl\u00f3rez L, Beltr\u00e1n-Velasco AI, et al. The role of adipokines in health and disease. Biomedicines 2023;11:1290. https:\/\/doi.org\/10.3390\/biomedicines11051290; PMID:\u00a037238961.","DOI":"10.3390\/biomedicines11051290"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"O\u2019Neill LAJ, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 2013;493:346\u201355. https:\/\/doi.org\/10.1038\/nature11862; PMID:\u00a023325217.","DOI":"10.1038\/nature11862"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Sharma K. Obesity, oxidative stress, and fibrosis in chronic kidney disease. Kidney Int Suppl (2011) 2014;4:113\u20137. https:\/\/doi.org\/10.1038\/kisup.2014.21; PMID:\u00a025401040.","DOI":"10.1038\/kisup.2014.21"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Decleves AE, Mathew AV, Cunard R, Sharma K. AMPK mediates the initiation of kidney disease induced by a high-fat diet. J Am Soc Nephrol 2011;22:1846\u201355. https:\/\/doi.org\/10.1681\/ASN.2011010026; PMID:\u00a021921143.","DOI":"10.1681\/asn.2011010026"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Ribari\u010d S.S. Diet and aging. Oxid Med Cell Longev 2012;2012:741468. https:\/\/doi.org\/10.1155\/2012\/741468; PMID:\u00a022928085.","DOI":"10.1155\/2012\/741468"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Ghosh S, Khazaei M, Moien-Afshari F, et al. Moderate exercise attenuates caspase-3 activity, oxidative stress, and inhibits progression of diabetic renal disease in db\/db mice. Am J Physiol Ren Physiol 2009;296:F700\u20138. https:\/\/doi.org\/10.1152\/ajprenal.90548.2008; PMID:\u00a019144689.","DOI":"10.1152\/ajprenal.90548.2008"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"De Vries APJ, Ruggenenti P, Ruan XZ, et al. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol 2014;2:417\u201326. https:\/\/doi.org\/10.1016\/S2213-8587(14)70065-8; PMID:\u00a024795255.","DOI":"10.1016\/s2213-8587(14)70065-8"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Sarafidis PA, Ruilope LM. Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. Am J Nephrol 2006;26:232\u201344. https:\/\/doi.org\/10.1159\/000093632; PMID:\u00a016733348.","DOI":"10.1159\/000093632"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Hall JE, do Carmo JM, da Silva AA, et al. Obesity, kidney dysfunction and hypertension: mechanistic links. Nat Rev Nephrol 2019;15:367\u201385. https:\/\/doi.org\/10.1038\/s41581-019-0145-4; PMID:\u00a031015582.","DOI":"10.1038\/s41581-019-0145-4"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Hall ME, do Carmo JM, da Silva AA, et al. Obesity, hypertension, and chronic kidney disease. Int J Nephrol Renovasc Dis 2014;7:75\u201388. https:\/\/doi.org\/10.2147\/IJNRD.S39739; PMID:\u00a024600241.","DOI":"10.2147\/ijnrd.s39739"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Helal I, Fick-Brosnahan GM, Reed-Gitomer B, Schrier RW. Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol 2012;8:293\u2013300. https:\/\/doi.org\/10.1038\/nrneph.2012.19; PMID:\u00a022349487.","DOI":"10.1038\/nrneph.2012.19"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Chang AR, Grams ME, Ballew SH, et al. Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium. BMJ 2019;364:k5301. https:\/\/doi.org\/10.1136\/bmj.k5301; PMID:\u00a030630856.","DOI":"10.1136\/bmj.k5301"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Garofalo C, Borrelli S, Minutolo R, et al. A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population. Kidney Int 2017;91:1224\u201335. https:\/\/doi.org\/10.1016\/j.kint.2016.12.013; PMID:\u00a028187985.","DOI":"10.1016\/j.kint.2016.12.013"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Xu H, Kuja-Halkola R, Chen X, et al. Higher body mass index is associated with incident diabetes and chronic kidney disease independent of genetic confounding. Kidney Int 2019;95:1225\u201333. https:\/\/doi.org\/10.1016\/j.kint.2018.12.019; PMID:\u00a030898340.","DOI":"10.1016\/j.kint.2018.12.019"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Zhu P, Herrington WG, Haynes R, et al. Conventional and genetic evidence on the association between adiposity and CKD. J Am Soc Nephrol 2021;32:127\u201337. https:\/\/doi.org\/10.1681\/ASN.2020050679; PMID:\u00a033127858.","DOI":"10.1681\/ASN.2020050679"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Herrington WG, Smith M, Bankhead C, et al. Body-mass index and risk of advanced chronic kidney disease: prospective analyses from a primary care cohort of 1.4 million adults in England. PLOS One 2017;12:e0173515. https:\/\/doi.org\/10.1371\/journal.pone.0173515; PMID:\u00a028273171.","DOI":"10.1371\/journal.pone.0173515"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Ejerblad E, Fored CM, Lindblad P, et al. Obesity and risk for chronic renal failure. J Am Soc Nephrol 2006;17:1695\u2013702. https:\/\/doi.org\/10.1681\/ASN.2005060638; PMID:\u00a016641153.","DOI":"10.1681\/ASN.2005060638"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Hsu CY, McCulloch CE, Iribarren C, et al. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006;144:21\u20138. https:\/\/doi.org\/10.7326\/0003-4819-144-1-200601030-00006; PMID:\u00a016389251.","DOI":"10.7326\/0003-4819-144-1-200601030-00006"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Yarnoff BO, Hoerger TJ, Shrestha SS, et al. Modeling the impact of obesity on the lifetime risk of chronic kidney disease in the United States using updated estimates of GFR progression from the CRIC study. PLOS One 2018;13:e0205530. https:\/\/doi.org\/10.1371\/journal.pone.0205530; PMID:\u00a030339684.","DOI":"10.1371\/journal.pone.0205530"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"D\u2019Agati VD, Chagnac A, De Vries APJ, et al. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. Nat Rev Nephrol 2016;12:453\u201371. https:\/\/doi.org\/10.1038\/nrneph.2016.75; PMID:\u00a027263398.","DOI":"10.1038\/nrneph.2016.75"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Qian L, Menez S, Hu D, et al. Safety and adequacy of kidney biopsy procedure in patients with obesity. Kidney360 2023;4:98\u2013101. https:\/\/doi.org\/10.34067\/KID.0006602022; PMID:\u00a036700910.","DOI":"10.34067\/KID.0006602022"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Kambham N, Markowitz GS, Valeri AM, et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001;59:1498\u2013509. https:\/\/doi.org\/10.1046\/j.1523-1755.2001.0590041498.x; PMID:\u00a011260414.","DOI":"10.1046\/j.1523-1755.2001.0590041498.x"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Praga M, Hern\u00e1ndez E, Morales E, et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant 2001;16:1790\u20138. https:\/\/doi.org\/10.1093\/ndt\/16.9.1790; PMID:\u00a011522860.","DOI":"10.1093\/ndt\/16.9.1790"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"KDIGO. Clinical practice guideline for the management of glomerular diseases. Kidney Int 2021;100:S1\u2013s276.","DOI":"10.1016\/j.kint.2021.05.021"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Panwar B, Hanks LJ, Tanner RM, et al. Obesity, metabolic health, and the risk of end-stage renal disease. Kidney Int 2015;87:1216\u201322. https:\/\/doi.org\/10.1038\/ki.2014.384; PMID:\u00a025517912.","DOI":"10.1038\/ki.2014.384"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Prospective Studies Collaboration, Whitlock G, Lewington S, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009;373:1083\u201396. https:\/\/doi.org\/10.1016\/S0140-6736(09)60318-4; PMID:\u00a019299006.","DOI":"10.1016\/s0140-6736(09)60318-4"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Ahmadi SF, Zahmatkesh G, Ahmadi E, et al. Association of body mass index with clinical outcomes in non-dialysis-dependent chronic kidney disease: a systematic review and meta-analysis. Cardiorenal Med 2015;6:37\u201349. https:\/\/doi.org\/10.1159\/000437277; PMID:\u00a027194995.","DOI":"10.1159\/000437277"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Ladhani M, Craig JC, Irving M, et al. Obesity and the risk of cardiovascular and all-cause mortality in chronic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant 2017;32:439\u201349. https:\/\/doi.org\/10.1093\/ndt\/gfw075; PMID:\u00a027190330.","DOI":"10.1093\/ndt\/gfw075"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Kang SY, Lee YH, Jeong SJ, et al. How obesity and metabolic syndrome affect cardiovascular events, progression to kidney failure and all-cause mortality in chronic kidney disease. Nephrol Dial Transplant 2024;39:778\u201387. https:\/\/doi.org\/10.1093\/ndt\/gfad214; PMID:\u00a037791396.","DOI":"10.1093\/ndt\/gfad214"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Kalantar-Zadeh K, Rhee CM, Chou J, et al. The obesity paradox in kidney disease: how to reconcile it with obesity management. Kidney Int Rep 2017;2:271\u201381. https:\/\/doi.org\/10.1016\/j.ekir.2017.01.009; PMID:\u00a028439569.","DOI":"10.1016\/j.ekir.2017.01.009"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Kalantar-Zadeh K, Rhee CM, Amin AN. To legitimize the contentious obesity paradox. Mayo Clin Proc 2014;89:1033\u20135. https:\/\/doi.org\/10.1016\/j.mayocp.2014.06.015; PMID:\u00a025092364.","DOI":"10.1016\/j.mayocp.2014.06.015"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Oga EA, Eseyin OR. The obesity paradox and heart failure: a systematic review of a decade of evidence. J Obes 2016;2016:9040248. https:\/\/doi.org\/10.1155\/2016\/9040248; PMID:\u00a026904277.","DOI":"10.1155\/2016\/9040248"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Kalantar-Zadeh K, Streja E, Kovesdy CP, et al. The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clin Proc 2010;85:991\u20131001. https:\/\/doi.org\/10.4065\/mcp.2010.0336; PMID:\u00a021037042.","DOI":"10.4065\/mcp.2010.0336"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Harhay MN, Kim Y, Milliron B-J, et al. Obesity weight loss phenotypes in CKD: findings from the chronic renal insufficiency cohort study. Kidney Int Rep 2023;8:1352\u201362. https:\/\/doi.org\/10.1016\/j.ekir.2023.04.022; PMID:\u00a037441488.","DOI":"10.1016\/j.ekir.2023.09.027"},{"key":"ref54","unstructured":"Conley MM, McFarlane CM, Johnson DW, et al. Interventions for weight loss in people with chronic kidney disease who are overweight or obese. Cochrane Database Syst Rev 2021;3:CD013119. https:\/\/doi.org\/10.1002\/14651858.CD013119.pub2; PMID:\u00a033782940."},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Bolignano D, Zoccali C. Effects of weight loss on renal function in obese CKD patients: a systematic review. Nephrol Dial Transplant 2013;28(Suppl 4):iv82\u201398. https:\/\/doi.org\/10.1093\/ndt\/gft302; PMID:\u00a024092846.","DOI":"10.1093\/ndt\/gft302"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Podadera-Herreros A, Arenas-de Larriva AP, Gutierrez-Mariscal FM, et al. Mediterranean diet as a strategy for preserving kidney function in patients with coronary heart disease with type 2 diabetes and obesity: a secondary analysis of CORDIOPREV randomized controlled trial. Nutr Diabetes 2024;14:27. https:\/\/doi.org\/10.1038\/s41387-024-00285-3; PMID:\u00a038755195.","DOI":"10.1038\/s41387-024-00285-3"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Kalantar-Zadeh K, Fouque D. Nutritional management of chronic kidney disease. N Engl J Med 2017;377:1765\u201376. https:\/\/doi.org\/10.1056\/NEJMra1700312; PMID:\u00a029091561.","DOI":"10.1056\/NEJMra1700312"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Zhang L, Wang Y, Xiong L, et al. Exercise therapy improves eGFR, and reduces blood pressure and BMI in non-dialysis CKD patients: evidence from a meta-analysis. BMC Nephrol 2019;20:398. https:\/\/doi.org\/10.1186\/s12882-019-1586-5; PMID:\u00a031664943.","DOI":"10.1186\/s12882-019-1586-5"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Valenzuela PL, Castillo-Garc\u00eda A, Saco-Ledo G, et al. Physical exercise: a polypill against chronic kidney disease. Nephrol Dial Transplant 2024;39:1384\u201391. https:\/\/doi.org\/10.1093\/ndt\/gfae062; PMID:\u00a038460948.","DOI":"10.1093\/ndt\/gfae062"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Neale EP, Rosario VD, Probst Y, et al. Lifestyle interventions, kidney disease progression, and quality of life: A systematic review and meta-analysis. Kidney Med 2023;5:100643. https:\/\/doi.org\/10.1016\/j.xkme.2023.100643; PMID:\u00a037235039.","DOI":"10.1016\/j.xkme.2023.100643"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Palmer SC, Maggo JK, Campbell KL, et al. Dietary interventions for adults with chronic kidney disease. Cochrane Database Syst Rev 2017;4:CD011998. https:\/\/doi.org\/10.1002\/14651858.cd011998.pub2; PMID:\u00a028434208.","DOI":"10.1002\/14651858.CD011998.pub2"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Kaesler N, Fleig S. Ten tips on how to manage obesity in the presence of CKD. Clin Kidney J 2024;17:sfae317. https:\/\/doi.org\/10.1093\/ckj\/sfae317; PMID:\u00a039588358.","DOI":"10.1093\/ckj\/sfae317"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389:2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563; PMID:\u00a037952131.","DOI":"10.1056\/NEJMoa2307563"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024;391:109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347; PMID:\u00a038785209.","DOI":"10.1056\/NEJMoa2403347"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Taal MW, Selby NM. Glucagon-like peptide-1 receptor agonists: new evidence of kidney and cardiovascular protection from the FLOW and SELECT trials. Am J Kidney Dis 2025;85:115\u20138. https:\/\/doi.org\/10.1053\/j.ajkd.2024.08.002; PMID:\u00a039341543.","DOI":"10.1053\/j.ajkd.2024.08.002"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Tilinca MC, Tiuca RA, Niculas C, et al. Future perspectives in diabesity treatment: semaglutide, a glucagon-like peptide 1 receptor agonist. Exp Ther Med 2021;22:1167. https:\/\/doi.org\/10.3892\/etm.2021.10601; PMID:\u00a034504612.","DOI":"10.3892\/etm.2021.10601"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Yao H, Zhang A, Li D, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ 2024;384:e076410. https:\/\/doi.org\/10.1136\/bmj-2023-076410; PMID:\u00a038286487.","DOI":"10.1136\/bmj-2023-076410"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 2021;9:653\u201362. https:\/\/doi.org\/10.1016\/S2213-8587(21)00203-5; PMID:\u00a034425083.","DOI":"10.1016\/s2213-8587(21)00203-5"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Singh S, Garg A, Tantry US, et al. Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients. Curr Probl Cardiol 2024;49:102403. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102403; PMID:\u00a038237815.","DOI":"10.1016\/j.cpcardiol.2024.102403"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Colhoun HM, Lingvay I, Brown PM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med 2024;30:2058\u201366. https:\/\/doi.org\/10.1038\/s41591-024-03015-5; PMID:\u00a038796653.","DOI":"10.1038\/s41591-024-03015-5"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383:1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816; PMID:\u00a032970396.","DOI":"10.1056\/NEJMoa2024816"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861\u20139. https:\/\/doi.org\/10.1056\/NEJMoa011161; PMID:\u00a011565518.","DOI":"10.1056\/NEJMoa011161"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020;383:2219\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2025845; PMID:\u00a033264825.","DOI":"10.1056\/nejmoa2025845"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Lee PC, Ganguly S, Goh SY. Weight loss associated with sodium\u2010glucose cotransporter\u20102 inhibition: a review of evidence and underlying mechanisms. Obes Rev 2018;19:1630\u201341. https:\/\/doi.org\/10.1111\/obr.12755; PMID:\u00a030253050.","DOI":"10.1111\/obr.12755"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Martin WP, White J, Lopez-Hernandez FJ, et al. Metabolic surgery to treat obesity in diabetic kidney disease, chronic kidney disease, and end-stage kidney disease; what are the unanswered questions? Front Endocrinol (Lausanne) 2020;11:289. https:\/\/doi.org\/10.3389\/fendo.2020.00289; PMID:\u00a033013677.","DOI":"10.3389\/fendo.2020.00289"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Sj\u00f6str\u00f6m L, Narbro K, Sj\u00f6str\u00f6m CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007;357:741\u201352. https:\/\/doi.org\/10.1056\/NEJMoa066254; PMID:\u00a017715408.","DOI":"10.1056\/NEJMoa066254"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Heneghan HM, Meron-Eldar S, Brethauer SA, et al. Effect of bariatric surgery on cardiovascular risk profile. Am J Cardiol 2011;108:1499\u2013507. https:\/\/doi.org\/10.1016\/j.amjcard.2011.06.076; PMID:\u00a021880286.","DOI":"10.1016\/j.amjcard.2011.06.076"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Sj\u00f6str\u00f6m L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 2014;311:2297\u2013304. https:\/\/doi.org\/10.1001\/jama.2014.5988; PMID:\u00a024915261.","DOI":"10.1001\/jama.2014.5988"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Li K, Zou J, Ye Z, et al. Effects of bariatric surgery on renal function in obese patients: a systematic review and meta analysis. PLOS One 2016;11:e0163907. https:\/\/doi.org\/10.1371\/journal.pone.0163907; PMID:\u00a027701452.","DOI":"10.1371\/journal.pone.0163907"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Navaneethan SD, Yehnert H, Moustarah F, et al. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009;4:1565\u201374. https:\/\/doi.org\/10.2215\/CJN.02250409; PMID:\u00a019808241.","DOI":"10.2215\/CJN.02250409"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Shulman A, Peltonen M, Sjostrom CD, et al. Incidence of end-stage renal disease following bariatric surgery in the Swedish Obese Subjects Study. Int J Obes (Lond) 2018;42:964\u201373. https:\/\/doi.org\/10.1038\/s41366-018-0045-x; PMID:\u00a029568103.","DOI":"10.1038\/s41366-018-0045-x"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Lee Y, Anvari S, Chu MM, et al. Improvement of kidney function in patients with chronic kidney disease and severe obesity after bariatric surgery: a systematic review and meta-analysis. Nephrology (Carlton) 2022;27:44\u201356. https:\/\/doi.org\/10.1111\/nep.13958; PMID:\u00a034375462.","DOI":"10.1111\/nep.13958"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Chang AR, Chen Y, Still C, et al. Bariatric surgery is associated with improvement in kidney outcomes. Kidney Int 2016;90:164\u201371. https:\/\/doi.org\/10.1016\/j.kint.2016.02.039; PMID:\u00a027181999.","DOI":"10.1016\/j.kint.2016.02.039"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Coleman KJ, Shu Y-H, Fischer H, et al. Bariatric surgery and risk of death in persons with chronic kidney disease. Ann Surg 2022;276:e784\u201391. https:\/\/doi.org\/10.1097\/SLA.0000000000004851; PMID:\u00a033914480.","DOI":"10.1097\/SLA.0000000000004851"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Sheetz KH, Gerhardinger L, Dimick JB, Waits SA. Bariatric surgery and long-term survival in patients with obesity and end-stage kidney disease. JAMA Surg 2020;155:581\u20138. https:\/\/doi.org\/10.1001\/jamasurg.2020.0829; PMID:\u00a032459318.","DOI":"10.1001\/jamasurg.2020.0829"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Carpio EM, Ashworth M, Asgari E, et al. Hypertension and cardiovascular risk factor management in a multi-ethnic cohort of adults with CKD: a cross sectional study in general practice. J Nephrol 2022;35:901\u201310. https:\/\/doi.org\/10.1007\/s40620-021-01149-0; PMID:\u00a034782969.","DOI":"10.1007\/s40620-021-01149-0"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Walker H, Sullivan MK, Jani BD, Gallacher K. Chronic kidney disease management in primary care: challenges and possible developments. Br J Gen Pract 2025;75:104\u20136. https:\/\/doi.org\/10.3399\/bjgp25X740829; PMID:\u00a040016109.","DOI":"10.3399\/bjgp25X740829"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Martinez YV, Benett I, Lewington AJP, et al. Chronic kidney disease: summary of updated NICE guidance. BMJ 2021;374:n1992. https:\/\/doi.org\/10.1136\/bmj.n1992; PMID:\u00a034489303.","DOI":"10.1136\/bmj.n1992"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Khan SS, Matsushita K, Sang Y, et al. Development and validation of the American Heart Association\u2019s PREVENT equations. Circulation 2024;149:430\u201349. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.067626; PMID:\u00a037947085.","DOI":"10.1161\/CIR.0000000000001230"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Sullivan MK, Carrero JJ, Jani BD, et al. The presence and impact of multimorbidity clusters on adverse outcomes across the spectrum of kidney function. BMC Med 2022;20:420. https:\/\/doi.org\/10.1186\/s12916-022-02628-2; PMID:\u00a036320059.","DOI":"10.1186\/s12916-022-02628-2"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Whitty CJM, MacEwen C, Goddard A, et al. Rising to the challenge of multimorbidity. BMJ 2020;368:l6964. https:\/\/doi.org\/10.1136\/bmj.l6964; PMID:\u00a031907164.","DOI":"10.1136\/bmj.l6964"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Sattar N, McMurray JJV, McInnes IB, et al. Treating chronic diseases without tackling excess adiposity promotes multimorbidity. Lancet Diabetes Endocrinol 2023;11:58\u201362. https:\/\/doi.org\/10.1016\/S2213-8587(22)00317-5; PMID:\u00a036460014.","DOI":"10.1016\/S2213-8587(22)00317-5"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"Colombijn JMT, Idema DL, van Beem S, et al. Representation of patients with chronic kidney disease in clinical trials of cardiovascular disease medications: a systematic review. JAMA Netw Open 2024;7:e240427. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.0427; PMID:\u00a038451526.","DOI":"10.1001\/jamanetworkopen.2024.0427"}],"container-title":["European Cardiology Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2025.33","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T12:18:50Z","timestamp":1760703530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2025.33"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":94,"URL":"https:\/\/doi.org\/10.15420\/ecr.2025.33","relation":{},"ISSN":["1758-3764","1758-3756"],"issn-type":[{"value":"1758-3764","type":"electronic"},{"value":"1758-3756","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"article-number":"e28"}}